Short answer
Neurocrine Biosciences Inc (NBIX) filed its Q3 2019 10-Q quarterly report on Nov 4, 2019 for the quarter ended Sep 30, 2019.
Neurocrine Biosciences Inc Q3 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $222.1M, up $70.3M from $151.8M YoY, driven by INGREZZA sales
- INGREZZA product sales $198.1M vs $111.3M YoY, strongest revenue contributor
- Q3 net income $53.8M vs $50.8M YoY, diluted EPS $0.56 vs $0.52
- Cash and investments $875.0M vs $866.9M at December 31, 2018; nine-month operating cash flow $49.5M vs $50.9M
- Near-term catalysts: KINECT-HD enrollment expected in Q4 2019; opicapone PDUFA date April 26, 2020
Risk Factors
- New Voyager collaboration risk: four-program agreement effective March 2019, with Voyager operational responsibility before specified transition events
- Opicapone regulatory risk: FDA NDA submitted June 2019, with PDUFA target date April 26, 2020
- Manufacturing concentration risk: limited suppliers for INGREZZA and active pharmaceutical ingredients, making replacement qualification time-consuming
- Competitive risk: INGREZZA competes with AUSTEDO, approved by FDA in August 2017, plus off-label medicines
- Debt and liquidity risk: $517.5 million of 2.25% convertible senior notes due May 15, 2024
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Neurocrine Biosciences Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.